Home Endocrinology & Hormones Estrogen/progestogen Receptor antagonist - Autophagy activator - Apoptosis related activator Fulvestrant For research use only.

Fulvestrant

Synonyms: ICI-182780, ZD 9238, ZM 182780

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.

Fulvestrant Chemical Structure

Fulvestrant Chemical Structure

CAS: 129453-61-8

Selleck's Fulvestrant has been cited by 150 publications

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Other Estrogen/progestogen Receptor Products

Related compound libraries

Choose Selective Estrogen/progestogen Receptor Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 Growth Inhibition Assay 1.3-1000 nM 48 h inhibits cell growth in a dose-dependent manner 24979294
MCF-7/LTED Growth Inhibition Assay 1.3-1000 nM 48 h inhibits cell growth in a dose-dependent manner 24979294
HCC1428 Growth Inhibition Assay 1.3-1000 nM 48 h inhibits cell growth in a dose-dependent manner 24979294
HCC1428/LTED Growth Inhibition Assay 1.3-1000 nM 48 h inhibits cell growth in a dose-dependent manner 24979294
LCC1 Function Assay 100 nM 48-144 h activates UPR signaling 24858277
LCC9 Function Assay 100 nM 48-144 h activates UPR signaling 24858277
MCF-7  Growth Inhibition Assay 100 nM 5 d inhibits cell growth to 10％ 24819550
mesangial  Function Assay 0.1-100 nM 48 h suppresses TGF-β1-induced type IV collagen 24793639
Mesangial Function Assay 0.1-100 nM 0.5 h inhibits TGF-β1-induced Smad2 phosphorylation via GPER 24793639
ER+ MCF-7/2a Growth Inhibition Assay IC50=0.004 μM 15324884
ER+ MCF-7 Growth Inhibition Assay 200 h IC50=0.21 nM 15324884
MCF-7  Function Assay 10 nM  72 h reverses the estrogen effect(IC50 1.9 × 10−9 M) 24908652
MCF-7  Growth Inhibition Assay IC50 of approximately 2 nM 23448346
H1975  Growth Inhibition Assay 3 μM 1 m increases the gefitinib sensitivity of H1975 cells  24268810
H1975 Function Assay 3 μM 1 m upregulates the level of Let-7c 24268810
MCF-7  Function Assay 100 nM  72 h reverses the protective effect of E2 in cell invasion 23936773
MCF-7  Function Assay 100 nM  24/48 h facilitates invasion through MMPs' modulation 23936773
BT474-tet-shMED1 Growth Inhibition Assay 0.1-5 μM 7 d increases +Dox induced cell death in a dose-dependent manner 23936234
ZR75-1-tet-shMED1  Growth Inhibition Assay 0.1-5 μM 7 d increases +Dox induced cell death in a dose-dependent manner 23936234
MCF-7-tet-shMED1 Growth Inhibition Assay 0.1-5 μM 7 d increases +Dox induced cell death in a dose-dependent manner 23936234
HepG2  Function Assay 0.01-10 μM 18 h  activates the ERE-mediated transcription of AF2ER 23733188
MCF-7L  Function Assay 100 nM  10 min/24 h/48 h results in EGFR, HER2 and HER3 phosphorylation at prolonged exposure 23686416
MCF-7L  Function Assay 100 nM  48 h induces upregulation of mRNA of EGFR ligand HB-EGF 23686416
MCF-7L Function Assay 100 nM  48 h induces EGFR family member activation required ER 23686416
C4-12  Function Assay 100 nM  48 h induces EGFR family member activation required ER 23686416
MCF-7L Function Assay 100 nM  24 h induces EGFR phosphorylation required HB-EGF function 23686416
MMQ  Function Assay 0-625 nM 72 h down-regulates the expression of estrogen receptor-α (ERα) 23523357
H1975  Growth Inhibition Assay 0.3125-10 μM 6 d inhibits cell growth in a dose-dependent manner 23399957
H1975  Apoptosis Assay 200 nM 72 h enhances erlotinib induced apoptosis 23399957
MCF-7  Growth Inhibition Assay 10/100/1000 nM 2/4/6 d DMSO inhibits cell growth in both dose- and time- dependent manner 23313506
MCF-7  Growth Inhibition Assay 100 nM 4 d DMSO induces a higher proportion of cells in the G1 phase  23313506
MLO-Y4  Function Assay 1 μM 1 h inhibits E2-induced Cx43 expression 23247057
MCF-7 Growth Inhibition Assay 100 nM 48 h abrogates the proliferative effect of moderate nitrosative stress 23216744
TG1-1  Function Assay 1 μM 24 h abrogates E2 induced accumulation of HIF-1α 23088607
TG1-1  Function Assay 1 μM 24 h abrogates E2 induced accumulation of PI3K 23088607
MCF7 Growth Inhibition Assay 100 nM 48 h leads to a similar loss in survival as with doxorubicin alone 23077249
MCF7 Growth Inhibition Assay 100 nM 48 h enhances nutlin-mediated cell death 23077249
MCF-7  Function Assay 6 h DMSO attenuates the fludioxonil- or fenhexamid-induced increase in miR-21 expression 23052036
MCF-7 Growth Inhibition Assay 100 nM/1 μM 5 d inhibits the stimulation of 17β-estradiol 22982765
MCF-7 Growth Inhibition Assay 100 nM 5 d inhibits the stimulation of fusarielin H 22982765
1471.1 Function Assay 100 nM 1 h EtOH  takes on a punctate staining pattern 22869106
MCF-7 Function Assay 100 nM 1 h EtOH  takes on a punctate staining pattern 22869106
HeLa Function Assay 100 nM 1 h EtOH  takes on a punctate staining pattern 22869106
COS-7  Function Assay 100 nM 1 h EtOH  takes on a punctate staining pattern 22869106
BG1L-OHTLT  Function Assay 10 nM 24 h  inhibits ERα expression 22652558
BG1L-ICILT Function Assay 10 nM 24 h  inhibits ERα expression 22652558
PC-9 Growth Inhibition Assay 0.003-30 μM 48 h inhibits cell growth in a dose-dependent manner 22560634
H1650 Growth Inhibition Assay 0.003-30 μM 48 h inhibits cell growth in a dose-dependent manner 22560634
H1975 Growth Inhibition Assay 0.003-30 μM 48 h inhibits cell growth in a dose-dependent manner 22560634
H1975 Function Assay 3 μM 3 h abrogates the phospho-EGFR induction by estrogen 22560634
H1975 Function Assay 3 μM 7 d induces EGFR expression 22560634
HTR-8 Function Assay 1 μM 1-48 h down-regulates the expression of IGFBP7 mRNA 22383111
JEG-3 Function Assay 1 μM 1-48 h down-regulates the expression of IGFBP7 mRNA 22383111
Huh7 Function Assay 50 μM 48 h inhibits genistein-mediated PON1 transactivation 22304296
201T Growth Inhibition Assay 5 μM 72 h inhibits cell growth significantly combined with vandetanib 22258476
A549  Growth Inhibition Assay 5 μM 72 h inhibits cell growth significantly combined with vandetanib 22258476
MCF-7 Function Assay 1 μM 24 h  downregulates ER expression induced by 4-OH-T   22049316
HCC-1428 Function Assay 1 μM 24 h  downregulates ER expression induced by 4-OH-T   22049316
MDA-361 Function Assay 1 μM 24 h  downregulates ER expression induced by 4-OH-T   22049316
ZR75-1 Function Assay 1 μM 24 h  downregulates ER expression induced by 4-OH-T   22049316
MCF-7 Growth Inhibition Assay 1 μM 5-10 d suppresses E2-induced growth inhibition 22049316
HCC-1428 Growth Inhibition Assay 1 μM 5-10 d suppresses E2-induced growth inhibition 22049316
MDA-361 Growth Inhibition Assay 1 μM 5-10 d suppresses E2-induced growth inhibition 22049316
ZR75-1 Growth Inhibition Assay 1 μM 5-10 d suppresses E2-induced growth inhibition 22049316
MCF-7/AC-1 Growth Inhibition Assay 0-0.2 μM 6 d inhibits cell growth modestly 22042792
MCF7 Growth Inhibition Assay 10 µM 48 h induces cell inhibition which can be enhanced by fibroblasts 22041887
MMQ Growth Inhibition Assay 0-625 nM 72 h produces statistically significant inhibition of cell proliferation  22015101
MMQ Function Assay 0-625 nM 72 h produces a statistically significant, dose-dependent reduction in PRL secretion 22015101
MCF7 Growth Inhibition Assay 0-1 μM 24-120 h inhibits the growth of MCF7-YB-1  21863258
HepG2 Apoptosis Assay 0.1 μM 24 h abolishes the estrogen-induced up-regulation of apoAI and apoM 21816233
MCF7–iFR3 Growth Inhibition Assay 20-100 nM 96 h enhances AP-induced cell growth inhibition 21792889
MCF7S Function Assay 1 μM 48 h downregulates overall ERα protein levels 21533195
MCF7 Function Assay 1 μM 48 h downregulates overall ERα protein levels 21533195
MCF7S Function Assay 1 μM 7 d attenuates tumorsphere formation and proliferation 21533195
MCF7S Growth Inhibition Assay 0.5/1 μM 7 d DMSO decreases cell expansion 21533195
T47D  Growth Inhibition Assay 4 nM 40 h suppresses cell growth moderately 21480391
BT474  Growth Inhibition Assay 4 nM 40 h suppresses cell growth moderately 21480391
T47D  Function Assay 10 nM 40 h downregulates ERα protein 21480391
BT474  Function Assay 10 nM 40 h downregulates ERα protein 21480391
MCF7 Function Assay 100 nM 7 d reduces ERα expression significantly 21396094
T47D  Function Assay 100 nM 7 d reduces ERα expression significantly 21396094
BT474  Function Assay 100 nM 7 d reduces ERα expression significantly 21396094
MDAMB361 Function Assay 100 nM 7 d reduces ERα expression significantly 21396094
MCF7 Growth Inhibition Assay 0.01-1 μM 7 d reduces cell growth significantly 21396094
T47D  Growth Inhibition Assay 0.01-1 μM 7 d reduces cell growth significantly 21396094
BT474  Growth Inhibition Assay 0.01-1 μM 7 d reduces cell growth significantly 21396094
MDAMB361 Growth Inhibition Assay 0.01-1 μM 7 d reduces cell growth significantly 21396094
MCF7 Function Assay 100 nM 7 d induces of ErbB3 and ErbB4 receptor expression and signalling 21396094
T47D  Function Assay 100 nM 7 d induces of ErbB3 and ErbB4 receptor expression and signalling 21396094
BT474  Function Assay 100 nM 7 d induces of ErbB3 and ErbB4 receptor expression and signalling 21396094
MDAMB361 Function Assay 100 nM 7 d induces of ErbB3 and ErbB4 receptor expression and signalling 21396094
MCF7 Function Assay 10 nM 96 h downregulates ER expression  21378333
MDA-MB-231 Function Assay 10 nM 96 h downregulates ER expression  21378333
SK-BR-3 Function Assay 10 nM 96 h downregulates ER expression  21378333
MCF-7 Growth Inhibition Assay 100 nM 72/96 h causes cell cycle arrest 21299862
MMQ Growth Inhibition Assay 0.008-625 nM 72 h inhibits cell growth in both time- and dose-dependent manner 20700755
MMQ Function Assay 0.008-625 nM 72 h inhibits PRL secretion in a dose-dependent manner 20700755
MMQ Function Assay 0.04-625 nM 72 h inhibits ERα expression 20700755
MMQ Function Assay 0.04-625 nM 72 h upregulates TGFβ3 and TGFβRII expression 20700755
MCF7 Function assay 6 days Induction of ERalpha degradation in human MCF7 cells assessed as inhibition of insulin-mediated cell proliferation after 6 days by Hoechst 33258 dye-based assay, IC50 = 0.00006 μM. 28296398
MCF7 Function assay Antagonist activity at ERalpha receptor in human MCF7 cells, IC50 = 0.0000631 μM. 26407012
MCF7 Function assay 4 hrs Induction of ERalpha degradation in human MCF7 cells in phenol red free RPMI medium containing 5% charcoal dextran-treated FBS incubated for 4 hrs by SP1 and anti-ER rabbit monocolnal antibody based in-cell Western assay, Activity = 0.0001 μM. 30086626
MCF7 Function assay 24 hrs Proteolysis targeting chimera activity in human MCF7 cells assessed as induction of E3 ubiquitin ligase-mediated ERalpha degradation by proteasome after 24 hrs by in-cell Western assay, IC50 = 0.0001 μM. 30128071
MCF7 Function assay Antagonist activity at progesterone receptor in human MCF cells assessed as estradiol-induced receptor response, IC50 = 0.0002089 μM. 26407012
MCF7 Function assay 24 hrs Downregulation of human ERalpha in human MCF-7 cells after 24 hrs by in-cell Western immunoassay method, IC50 = 0.0003 μM. 28657320
MCF7 Function assay 4 hrs Induction of estrogen receptor-alpha degradation in human MCF7 cells after 4 hrs by in-cell western assay, EC50 = 0.0004 μM. 25879485
MCF7 Function assay 4 hrs Decrease in estrogen receptor alpha level in human MCF7 cells after 4 hrs by in-cell western assay, EC50 = 0.0004 μM. 26463130
MCF7 Function assay Antagonist effect on transcriptional activation in MCF-7 cells expressing estrogen receptor alpha, IC50 = 0.00047 μM. 10673099
MCF7 Function assay Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells, IC50 = 0.00049 μM. 9154963
MCF7 Function assay 24 hrs Antagonist activity at estrogen receptor in human MCF7 cells assessed as inhibition of 17beta-estradiol-mediated transcriptional activation after 24 hrs by luciferase reporter gene assay, IC50 = 0.0006 μM. 25879485
MCF7 Function assay 18 to 24 hrs Induction of ERalpha degradation in human MCF7 cells after 18 to 24 hrs by Western blot analysis, IC50 = 0.001 μM. 28296398
MCF7 Function assay 18 hrs Induction of ERalpha degradation in human MCF7 cells after 18 hrs by Western blot analysis, IC50 = 0.0012 μM. 28296398
MCF7 Function assay 18 to 24 hrs Induction of selective estrogen receptor alpha degradation in human MCF7 cells after 18 to 24 hrs by in-cell Western analysis, IC50 = 0.0012 μM. 29562737
MCF7 Function assay 24 hrs Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of estrogen-induced transcription preincubated overnight followed by estrogen addition measured after 24 hrs by dual luciferase reporter gene assay, IC50 = 0.0034 μM. 28296398
MCF7 Function assay 24 hrs Induction of selective estrogen receptor alpha degradation in human MCF7 cells harboring TK-ERE-Luc assessed as reduction in estradiol-induced transcriptional activity after 24 hrs by luciferase reporter gene assay, IC50 = 0.0034 μM. 29562737
COS7 Function assay Antagonist activity at estrogen receptor beta ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay, IC50 = 0.0038 μM. 19863083
MCF7 Function assay 24 hrs Induction of selective estrogen receptor alpha degradation in human MCF7 cells harboring TK-ERE-Luc assessed as reduction in estradiol-induced GREB1 mRNA expression after 24 hrs by TaqMan assay, IC50 = 0.0038 μM. 29562737
COS7 Function assay Antagonist activity at estrogen receptor alpha ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay, IC50 = 0.004 μM. 19863083
Rosetta 2 DE3 competent cell Function assay 1 hr Displacement of [3H]-estradiol from recombinant human N-terminal His-tagged ERalpha LBD harboring C381S/C417S/C530S mutant expressed in Rosetta 2 DE3 competent cells after 1 hr by SPA binding assay, IC50 = 0.0084 μM. 28296398
HepG2 Function assay 16 hrs Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay, EC50 = 1.95 μM. 23688559
MCF7 Function assay 10 uM 3 days Inhibition of increase in proliferation of estrogen receptor expressing MCF7 cells at 10 uM after 3 days 17275315
MVLN Function assay 24 hrs Activity at ER assessed as suppression of estrogen response element-driven gene transactivation in MVLN cells after 24 hrs by luciferase reporter gene assay 17275315
T47D Function assay 5 uM Agonist activity at human ERalpha in T47D cells assessed as enhancement of AP1-driven transactivation at 5 uM by luciferase reporter assay relative to DMSO 17337183
MCF7 Function assay 45 mins Binding affinity to estrogen receptor alpha in human MCF7 cells assessed as inhibition of [3H]E2 accumulation after 45 mins by whole cell competition binding assay 19133777
MCF7 Function assay 24 hrs Down regulation of estrogen receptor alpha expression in human MCF7 cells after 24 hrs by Western blot analysis 19133777
MCF7 Function assay 100 nM 24 hrs Down regulation of estrogen receptor alpha expression in human MCF7 cells at 100 nM after 24 hrs by immunofluorescence staining 19133777
MCF7:D5L Function assay 1 uM Antagonist activity at ERalpha in human MCF7:D5L cells assessed as inhibition of ERE-dependent luciferase expression at 1 uM 19845386
HEK293 Function assay 1 uM Antagonist activity at ERbeta in HEK293 cells assessed as inhibition of ERE-dependent luciferase expression at 1 uM 19845386
Ishikawa Function assay 1 uM Antagonist activity at estrogen receptor in human Ishikawa cells assessed as inhibition of ERE-dependent alkaline phosphatase levels at 1 uM 19845386
HeLa Function assay 1 uM 48 hrs Antagonist activity at human ERalpha expressed in human HeLa cells coexpressing ERE-E1b-Luc assessed as inhibition of estradiol-induced transcriptional activation at 1 uM after 48 hrs by luciferase reporter gene assay 20621492
HeLa Function assay 100 nM 20 to 24 hrs Antagonist activity at LBD of ERalpha receptor in human HeLa cells assessed as blockade of SRC-1 binding to receptor at 100 nM after 20 to 24 hrs by luciferase reporter gene assay 23448346
MCF7 Function assay 10 nM 72 hrs Inhibition of 17beta-estradiol-induced in ERalpha positive human MCF7 cells proliferation assessed as [3H]-thymidine incorporation at 10 nM after 72 hrs by liquid scintillation counting 24908652
MCF7 Function assay 1 uM 20 hrs Induction of estrogen receptor-alpha degradation in human MCF7 cells at 1 uM after 20 hrs by Western blot analysis 25879485
MCF7 Function assay 0.01 to 300 nM 48 hrs Degradation activity of ERalpha receptor in human MCF7 cells at 0.01 to 300 nM after 48 hrs by Western blot analysis 26407012
Neuro2a Function assay 1 uM Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis 26789657
MCF-7 Function assay 3 nM, 30 nM, 300 nM, 3 uM 24 hrs Downregulation of ERalpha in human MCF-7 cells assessed as reduction of estradiol-induced GREB1 mRNA levels at 3 x 10'-9 M, 3 x 10'-8 M, 3 x 10'-7 M, 3 x 10'-6 M after 24 hrs by RT-PCR method 28657320
MCF-7 Function assay 3 nM, 30 nM, 300 nM, 3 uM 24 hrs Downregulation of ERalpha in human MCF-7 cells assessed as reduction of estradiol-induced PgR mRNA levels at 3 x 10'-9 M, 3 x 10'-8 M, 3 x 10'-7 M, 3 x 10'-6 M after 24 hrs by RT-PCR method 28657320
MCF-7 Function assay 3 nM, 30 nM, 300 nM, 3 uM 24 hrs Downregulation of ERalpha in human MCF-7 cells assessed as reduction of estradiol-induced pS2 mRNA levels at 3 x 10'-9 M, 3 x 10'-8 M, 3 x 10'-7 M, 3 x 10'-6 M after 24 hrs by RT-PCR method 28657320
MCF7 Function assay 10 uM 24 hrs Induction of selective estrogen receptor alpha degradation in human MCF7 cells at 10 uM after 24 hrs by Western blot analysis 29562737
Click to View More Cell Line Experimental Data

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro
In vitro Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]
Cell Research Cell lines MCF-7 breast cancer cells
Concentrations 2.9 nM
Incubation Time 5 days
Method MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
Experimental Result Images Methods Biomarkers Images PMID
Western blot MDM2 / ER p-ErbB3 Y1289 / ErbB3 / p-ErbB4 Y1056 / ErbB4 / p-AKT / AKT / p-ERK / ERK ErbB3 ERα 24747123
Immunofluorescence IGF-1R / Erα Snail / E-cadherin 19815064
Growth inhibition assay Cell viability 29787591
In Vivo
In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]
Animal Research Animal Models The human breast cancer xenografts MCF-7 in nude mice
Dosages 5 mg/mouse
Administration s.c. injection
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05905341 Withdrawn Breast Cancer|Ovarian Cancer|Liposarcoma|Non-small Cell Lung Cancer (NSCLC)|Endometrial|Solid Tumors Pfizer January 15 2024 Phase 1
NCT05963984 Recruiting Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer Carrick Therapeutics Limited|Pfizer December 14 2023 Phase 2
NCT06129786 Recruiting Breast Cancer Centro di Riferimento Oncologico - Aviano May 18 2023 --
NCT05191004 Withdrawn Advanced Breast Cancer|Metastatic Breast Cancer|Breast Cancer|Breast Carcinoma|Cancer of the Breast|Cancer of Breast|Malignant Tumor of Breast|Breast Tumor Nuvation Bio Inc. September 2022 Phase 1|Phase 2
NCT05082025 Active not recruiting Endometrial Cancer|Ovarian Cancer M.D. Anderson Cancer Center|Bayer September 27 2022 Phase 2

Chemical lnformation & Solubility

Molecular Weight 606.77 Formula

C32H47F5O3S
CAS No. 129453-61-8 SDF Download Fulvestrant SDF
Smiles CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (164.8 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is there any information for the half-life of fulvestrant (Cat No.S1191)?

Answer:
S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr